PD-L1 expression predicts efficacy in the phase II SPiReL trial with MVP-S, pembrolizumab, and low-dose CPA in R/R DLBCL.
Irina AmitaiKim RoosIran RashediYidi JiangKathryn MangoffGail KleinNicholas ForwardDouglas A StewartPierre LaneuvilleIsabelle Bence-BrucklerJoy MangelGeorge A TomlinsonNeil L BerinsteinPublished in: European journal of haematology (2023)
This immunotherapy combination was found to be active and safe in this clinically challenging patient population.